Growth, immunophenotype and interleukin-6 level of bone marrow stromal cells in patients with multiple myeloma and acute leukemia
- PubMed: 16928303
Abstract
The aim of this study was to investigate the growth, immunophenotype and interleukin-6 (IL-6) level of bone marrow stromal cells (BMSC) in patients with acute leukemia (AL) and multiple myeloma (MM). BMSC was cultured by wall-adhesion method and the growth of BMSC was observed. The immunophenotype and cell cycle of BMSC were detected by flow cytometry. The level of interleukin 6 (IL-6) in BMSC culture system was detected by ELISA. The results showed that the primary (17.3 7.8 days) and continuous (10.3 3.5 days) growth cycle of BMSC in patients with AL were significantly shorter than those in patients with MM (26.5 6.3 and 16.5 4.1 days respectively), and shorter than those in normal controls (25.8 6.3 and 17.5 2.4 days) respectively. Similarly, S + G2% (17.4 3.6%) of BMSC in patients with AL was significantly higher than those in patients with MM (8.5 2.2%) and in normal controls (8.9 2.3%). All of the three groups showed positive antigen expressions with CD29 and CD44 were 100%, while CD138, CD34, CD54, CD56 positive were not expressed and CD106 was partially expressed positive. The supernatant IL-6 level of BMSC system in MM patients (1288.5 736.7 pg/ml) was significantly higher than those in AL patients (859.3 203.1 pg/ml) and normal controls (850.9 129.5 pg/ml). It is concluded that the growth, S + G2% of cell cycle and IL-6 level of BMSC in patients with MM, AL and normal control are significantly different, whereas the antigen expressions are similar.
Sign up today - FREE
Mendeley saves you time finding and organizing research. Learn more
- All your research in one place
- Add and import papers easily
- Access it anywhere, anytime